Medical Properties Trust (MPW)
(Delayed Data from NYSE)
$5.04 USD
0.00 (0.00%)
Updated May 24, 2024 04:00 PM ET
After-Market: $5.07 +0.03 (0.60%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Medical Properties (MPW) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$5.11 | $7.00 | $4.00 | 1.39% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Medical Properties comes to $5.11. The forecasts range from a low of $4.00 to a high of $7.00. The average price target represents an increase of 1.39% from the last closing price of $5.04.
Analyst Price Targets (9 )
Broker Rating
Medical Properties currently has an average brokerage recommendation (ABR) of 3.42 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 3.33 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, one is Strong Buy, representing 8.33% of all recommendations. A month ago, Strong Buy made up 8.33%, while Buy represented 8.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 1 | 1 | 1 | 1 | 2 |
Buy | 0 | 0 | 1 | 2 | 2 |
Hold | 7 | 7 | 6 | 4 | 5 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 3 | 3 | 3 | 4 | 4 |
ABR | 3.42 | 3.42 | 3.33 | 3.42 | 3.21 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/10/2024 | Colliers Securities | Barry Oxford | Moderate Buy | Hold |
4/8/2024 | Truist Securities | Michael Lewis | Hold | Hold |
3/1/2024 | Exane BNP Paribas | Nathan D Crossett | Hold | Strong Buy |
2/29/2024 | Not Identified | Not Identified | Strong Sell | Strong Sell |
1/5/2024 | KeyBanc Capital Markets | Austin Wurschmidt | Strong Buy | Hold |
1/3/2024 | Mizuho SecuritiesUSA | Vikram Malhotra | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.42 |
ABR (Last week) | 3.42 |
# of Recs in ABR | 12 |
Average Target Price | $5.11 |
LT Growth Rate | 8.00% |
Industry | REIT and Equity Trust - Other |
Industry Rank by ABR | 147 of 252 |
Current Quarter EPS Est: | 0.24 |